Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 4Uterine Cervical Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Adenocarcinoma of Lung 2Unspecified Childhood Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Limited Stage Small Cell Lung Cancer 1Laryngeal Diseases 1Hypoxia 1HCC 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Sorafenib 2nimotuzumab 1lenvatinib 1atezolizumab 1Tirapazamine 1Stents 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Immune Checkpoint Inhibitors 1Hematologic Tests 1Ethiodized Oil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HCC × Tirapazamine × Clear all
NCT06844357 2025-04-06

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Zhejiang Raygene Pharmaceuticals Co., Ltd

Phase 2/3 Recruiting
300 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡